Global EYLEA drug market size is expected to reach US$ 14.30 Bn by 2030, from US$ 8.79 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period. EYLEA (aflibercept) is an anti-vascular endothelial growth factor (Anti-VEGF) medication used to treat several eye disorders including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). It works by inhibiting the abnormal growth of blood vessels in the eye, thereby preventing leakage and swelling that can cause vision loss. EYLEA helps improve vision and reduce the risk of blindness in patients suffering from these retinal diseases.

Rising prevalence of diabetes and age-related eye diseases is a major factor driving the EYLEA drug market growth. Growing geriatric population which is more susceptible to eye disorders is also fueling the demand for EYLEA. Moreover, the rising awareness about retinal diseases and the availability of favorable reimbursement for EYLEA injections are other factors propelling the market growth.

Global Eylea Drug Market Drivers

• Increasing geriatric population: Increasing geriatric population globally will aid in the market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) in October 1, 2022, the number of people aged 60 years and older outnumbered children younger than 5 years, in 2020,
• Strong Clinical Efficacy Profile of EYLEA: EYLEA has demonstrated strong efficacy in treating wet AMD and other retinal diseases in multiple large clinical trials, thereby leading to its approval for these indications. In the VIEW 1 and VIEW 2 trials, EYLEA showed non-inferiority and comparable efficacy to ranibizumab in improving vision in wet AMD patients. The VIVID and VISTA trials established EYLEA’s efficacy in significantly improving vision and reducing central retinal thickness in DME patients. Such positive clinical data has augmented trust in the performance of EYLEA, thereby encouraging its adoption.

Global Eylea Drug Market Opportunities

• High growth potential in emerging countries: Emerging markets such as Asia Pacific and Latin America present significant growth opportunities for EYLEA, due to the high patient pool, growing healthcare expenditure, and expanding access to eye care in these regions. For instance, according to the data published by the World Bank, in April 2023, India’s health expenditure was 2.96% of gross domestic product in 2020.

Global Eylea Drug Market Restraints

• Side Effects: Side effects of eylea are expected to hinder the market growth over the forecast period. There few side effects of eylea which includes increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

Counterbalance: The key market players need to focus on reducing the side effects of the EYLEA drug at the time of its manufacturing processes, so that it gets accepted by the population and help in driving the market growth of the EYLEA drug.

Analyst’s View on Global Eylea drug market:

Global eylea drug market is expected to witness high growth over the forecast period due to increasing prevalence of eye diseases, as well as increasing geriatric population globally which is expected to drive the global EYLEA drug market growth. Moreover, the patent of the brand is expected to expire after in 2025, which is expected to generate high revenues.

• Strategic collaborations and alliances: Increasing strategic collaboration among the industry players will aid in the market growth over the forecast period. For instance, in December 21, 2020, Bayer, a pharmaceutical company, announced its collaboration with social healthcare venture Arogya Finance, to introduce the Eylea Easy Pay Program in India to provide flexible and affordable payment solutions to help patients in India, accessing Eylea (aflibercept solution) treatment.

Global EYLEA Drug Market Regional Insights

• North America is expected to be the largest market for EYLEA drug market during the forecast period, accounting for over 40.2% of the market share in 2023. The growth of the market in North America is due to increasing prevalence of eye diseases in North America.
• The Europe market is expected to be the second-largest market for eylea drug market, accounting for over 25.4% of the market share in 2023. The growth of the market in Europe is due to rising geriatric population.
• The Asia Pacific market is expected to be the fastest-growing market for eylea drug market, with a CAGR of over 21.3% during the forecast period. The growth of the market in Asia Pacific is due to rising diabetes population.

Figure 1. Global EYLEA Drug Market Share (%), By Region, 2023

Bayer, Regeneron Pharmaceuticals, Coherus BioSciences, Inc., and Klinge Biopharma.

New product launches

• On August 18, 2023, Regeneron Pharmaceuticals, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved EYLEA HD (aflibercept) injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR)

Acquisition and partnerships

• In January 09, 2023, Coherus BioSciences, Inc., a biotechnology company, announced that it has executed a binding term sheet with Klinge Biopharma GmbH, a pharmaceutical company, for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea (aflibercept), in the U.S.

• By Indication:
• • Wet Age-Related Macular Degeneration (Wet AMD)
  • Diabetic Retinopathy (DR)
  • Diabetic Macular Edema (DME)
  • Retinal Vein Occlusion (RVO)
  • Myopic Choroidal Neovascularization (mCNV)
  • Others
• By End User:
• • Hospitals
  • Ophthalmic Clinics
  • Others
• By Region:
• • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa